Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MPO | P05164 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | ACE | P12821 | 4/20 | 0.61 |
| ▸ | ITGB2 | P05107 | 4/20 | 0.60 |
| ▸ | ICAM1 | P05362 | 4/20 | 0.60 |
| ▸ | ITGAL | P20701 | 4/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Golotimod SCHEMBL14790029 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| Golotimod SCHEMBL12966340 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| Golotimod SCHEMBL727944 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| Golotimod SCHEMBL1768729 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| Golotimod SCHEMBL726291 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| Golotimod SCHEMBL12818886 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| Golotimod SCHEMBL29622906 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| Golotimod SCHEMBL726938 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| Orilotimod SCHEMBL29379690 | 1.00 | KDM4E (0.65) | KDM4EMEN1LMNAMPOMAPT | |
| SCHEMBL645413 | 0.93 | ERAP2 (0.60) | KDM4EMEN1LMNAMPOMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225341-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF THYMODEPRESSIN AND PROCESSES FOR THEIR MANUFACTURE | APOTEX TECHNOLOGIES INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150225341-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF THYMODEPRESSIN AND PROCESSES FOR THEIR MANUFACTURE | APOTEX TECHNOLOGIES INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150011484-A1 | PRODRUGS OF D-GAMMA-GLUTAMYL-D-TRYPTOPHAN AND D-GAMMA-GLUTAMYL-L-TRYPTOPHAN | APTOEX TECHNOLOGIES, INC. (CA) | 2015-01-08 | — | — | US | disclosed |
| US-20150011484-A1 | PRODRUGS OF D-GAMMA-GLUTAMYL-D-TRYPTOPHAN AND D-GAMMA-GLUTAMYL-L-TRYPTOPHAN | APTOEX TECHNOLOGIES, INC. (CA) | 2015-01-08 | — | — | US | disclosed |
| US-20140343050-A1 | PRODRUGS OF D-ISOGLUTAMYL-[D/L]-TRYPTOPHAN | APTOEX TECHNOLOGIES, INC. (CA) | 2014-11-20 | — | — | US | disclosed |
| US-8735602-B2 | Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture | APOTEX TECHNOLOGIES INC. (CA) | 2014-05-27 | — | — | US | disclosed |
| US-8735602-B2 | Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture | APOTEX TECHNOLOGIES INC. (CA) | 2014-05-27 | — | — | US | disclosed |
| US-8664262-B2 | Crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan | APOTEX TECHNOLOGIES INC. (CA) | 2014-03-04 | — | — | US | disclosed |
| US-8664262-B2 | Crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan | APOTEX TECHNOLOGIES INC. (CA) | 2014-03-04 | — | — | US | disclosed |
| EP-2691370-A1 | PRODRUGS OF D-GAMMA-GLUTAMYL-D-TRYPTOPHAN AND D-GAMMA- GLUTAMYL-L-TRYPTOPHAN | Apotex Technologies Inc. (CA) | 2014-02-05 | — | — | EP | disclosed |
| US-20100056803-A1 | Pharmaceutically Acceptable Salts of Thymodepressin and Processes for their Manufacture | APOTEX TECHNOLOGIES INC. (CA) | 2010-03-04 | — | — | US | disclosed |
| US-20100056803-A1 | Pharmaceutically Acceptable Salts of Thymodepressin and Processes for their Manufacture | APOTEX TECHNOLOGIES INC. (CA) | 2010-03-04 | — | — | US | disclosed |
| US-20100029742-A1 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2010-02-04 | — | — | US | disclosed |
| US-20100029742-A1 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2010-02-04 | — | — | US | disclosed |
| US-20100016243-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | US | disclosed |
| US-20100016243-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | US | disclosed |
| WO-2008098355-A1 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008074128-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF THYMODEPRESSIN AND PROCESSES FOR THEIR MANUFACTURE | APOTEX TECHNOLOGIES INC. (CA) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008064465-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL- D-TRYPTOPHAN | APOTEX TECHNOLOGIES INC. (CA) | 2008-06-05 | — | — | WO | disclosed |
| US-5916878-A | DIPEPTIDE OF EITHER GAMMA-GLUTAMYL-L-TRYPTOPHAN OR BETA-ASPARTYL-L-TRYPTOPHAN; ADMINISTERING TO THE PATIENTS TO REDUCE THE RISKS INFECTIONS FROM MICROORGANISM | Wei, Edward T. (US) | 1999-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029742-A1 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | TPH1, AADAT, KYNU | KDM4E 2612/4885MEN1 907/4885LMNA 2140/4885 |
| US-20140343050-A1 | PRODRUGS OF D-ISOGLUTAMYL-[D/L]-TRYPTOPHAN | TPH1, TYMS, TDO2 | KDM4E 3178/4885MEN1 2526/4885LMNA 1457/4885 |
| US-20100056803-A1 | Pharmaceutically Acceptable Salts of Thymodepressin and Processes for their Manufacture | TPH1, CACNA1G, CACNA1S | KDM4E 2406/4885MEN1 923/4885LMNA 3219/4885 |
| US-20100016243-A1 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN | DDC, AADAT, GLUL | KDM4E 1255/4885MEN1 2768/4885LMNA 1841/4885 |
| US-20150011484-A1 | PRODRUGS OF D-GAMMA-GLUTAMYL-D-TRYPTOPHAN AND D-GAMMA-GLUTAMYL-L-TRYPTOPHAN | TPH1, GCG, GLUL | KDM4E 3537/4885MEN1 1065/4885LMNA 625/4885 |
| US-20150225341-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF THYMODEPRESSIN AND PROCESSES FOR THEIR MANUFACTURE | TMSB10, TMSB4X, TSLP | KDM4E 1489/4885MEN1 1217/4885LMNA 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.